Akademischer Bericht 2005 - Geburtshilfe - UniversitätsSpital Zürich

Professur/Forschungsbereich: Zisch, Andreas
Biophotonic imaging to study transcriptional regulation of angiogenesis response in tissue in response
to fast or slow release of vascular endothelial growth factor from fibrin implants
Although vascular endothelial cell growth factor (VEGF) has been described as a potent angiogenic
growth factor, its application in therapeutic angiogenesis remains difficult: blood vessels formed by exposure
VEGF tend to be malformed and leaky. In nature, the principal form of this factor possesses
a binding site for extracellular matrix components that may maintain it in the immobilized state until
released by local cellular enzymatic activity.
We have previously reported a mutant form of VEGF, a2PI1-8-VEGF121, that mimics this concept of
matrix binding and cell-mediated release, working in the context of the surgically-relevant matrix fibrin
(CircRes (2004), 94, 1124-32) (slow release formulation). We demonstrated that this engineered VEGF
formulation induces blood vessel formation more potently than conventional formulations of wild-type
VEGF121 in fibrin (fast release formulation), and that those vessels possess more normal morphologies
at the microscopic and ultrastructural levels.
In the present study, we apply non-invasive Xenogen biophotonic imaging method and a subcutaneous
implant model in VEGFR2-luc-mice to examine over weeks the transcriptional regulation of angiogenesis
in tissue exposed to a2PI1-8-VEGF121 (slow release formulation) versus wild-type VEGF121 (fast
release formulation) release from fibrin implants.
01.05.2004-31.12.2006
Professur/Forschungsbereich: Zisch, Andreas
Changes in platelet activity during pregnancy and postpartum
In pregnancy platelets (Tc) can change their activity status (AS). So far the AS has been determined
by complicated methods of surface antibody detection. A new method uses the morphological changes
of activated Tc to determine the AS. The swelling and the degranulation of the Tc is measured by laser
light scatter under 2 angles in flowcytometry. The aim of this study was to determine standard values for
this new method in normal pregnancy and compare it to complicated pregnancies, e.g. preeclampsia.
01.01.2002-31.05.2005
Professur/Forschungsbereich: Zisch, Andreas
Digital ”mother’s record”
01.01.2005-31.12.2006
Professur/Forschungsbereich: Zisch, Andreas
Effects of recombinant human Erythropoietin (rhEPO) on plasma volume, hematocrit and physical performance
The aim of this interdisciplinary investigationis to study the effect of rhEPO on plasma volume, hematocrit
and physical performance in male volunteers. Physical performance will be studied by the Dept.
of Sports Physiology (Prof. U. Boutellier), while the measurements of plasma volume (ICG) and red
cell volume (Na-Fluorescein) will be done in the Dept. of Obstetrics, University Hospital Zurich, with the
support of the Dept. Anesthesiology, University Hospital Munich.
The study were begun in 2002 and interrupted after methodological problems with the measurement of
blood volume. The study were started again winter 2003/2004.
01.02.2002-31.12.2005
Professur/Forschungsbereich: Zisch, Andreas
Efficacy of intravenous Venofer compared to oral Tardyferon in the prophylaxis of iron deficiency anemia
in pregnant women. An open randomised study
To compare in an open randomised, single centre, phase IV study with 260 pregnant women randomly
assigned to 2 parallel groups, the efficacy of i.v. iron(III)-hydroxide sucrose (Venofer, 200 mg at week 20
and 30) versus oral iron sulphate (Tardyferon, 80 mg/day from week 15.0 until discharge after delivery).
Primary endpoints: the percentage of pregnant women with hemoglobin < 11.0 g/dl.
Klinik für Geburtshilfe
Akademischer Bericht 2005
12